June 30th, 2023

Within our cells, genes can be switched 'on' or 'off', very similar to turning on a light or muting a TV. Scientists have identified a specific gene, called EZH2 that plays a crucial role in this process. When EZH2 is overly active, it can contribute to the development of diseases like prostate cancer.

By comprehending and managing the EZH2 gene, researchers hope to develop novel strategies for cancer treatment.

The EZH2 Gene and Prostate Cancer

The EZH2 gene is part of a group that influences cell growth and transformation. If this gene is excessively active, it can cause uncontrolled cell growth leading to prostate cancer.

Researchers believe that by regulating this gene, they can activate the good genes responsible for controlling cell growth. This breakthrough could provide a new approach to treating complex diseases like cancer.

Epigenetic therapies represent a promising area of prostate cancer treatment in treating cancers and other diseases in new ways.

Pfizer Clinical Trial for Metastatic Prostate Cancer Now Enrolling

Pfizer, Inc. is conducting a randomized, open-label, multi-center dose escalation and dose expansion study to evaluate if an investigational oral medicine is safe and effective for the treatment of metastatic castration resistant prostate cancer (mCRPC).

This study will allow researchers to compare enzalutamide (standard of care) versus enzalutamide in addition to an oral investigational medication.

Learn more click here

PHENTrials.com hosts approximately 500 prostate cancer clinical trials that are categorized for patients to find trials that are a match for where they are on their prostate cancer journey.

Patients can use PHEN’s “Find-Your-Trial” search tool to easily find appropriate trials. PHEN also provides clinical trials navigation support for patients.

Visit: PHENTrials.com